This November, the AMP Study (also known as HVTN 703/HPTN 081) will bring a fresh approach to HIV prevention research. The Phase 2B study is inspired by vaccine research, which seeks to arm the immune system to resist HIV infection — but it skips a step by directly giving HIV-negative people antibodies rather than using a vaccine to trigger the desired antibody response. However, the AMP study is notable for more than this new approach to HIV prevention. It’s also engaging transgender people and people of color at every step of the process, and is the first HIV prevention clinical efficacy trial to explicitly name transgender men as an eligible population to be included in the study.
As explained by HIV Vaccine Trials Network (HVTN)’s lead behavioral scientist, Michele Andrasik, Ph.D., the AMP Study is taking “a true community-based participatory approach.” Trans people and people of color have been involved in writing the protocol, crafting language on enrollment forms and reviewing informed consent and educational materials. Trans people have been employed to fill clinic staff openings, and professional consultants with lived trans experience have been hired to train cisgender (non-transgender) clinicians and staff.
Read more of Brandyn’s new article at TheBodyPRO.com